August, 07 2025 Thursday 22:21 Hrs
  • SENSEX :   80,623.26

  • Commodity broking firm in India79.27( 0.10%) 07-Aug-2025
top-arrow-market
Sensex 80623.26 79.27  (0.10) 07-Aug-2025
Previous Day Close
80543.99
Today's High/Low
High Low
  •  
  •  
80737.55 79811.29

Company News Details

Dr Reddys Laboratories Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
500124
INE089A01031
345.7618998
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
DRREDDY
14.49
99907.78
EPS(TTM)
Face Value()
Div & Yield %
82.6
1
0.67
 

Dr Reddys Lab gains after Q1 PAT jumps 2% YoY to Rs 1,418 cr
Jul 24,2025
Profit before tax (PBT) stood at Rs 1,905 crore in Q1 FY26, up 1.2% YoY

EBITDA for the quarter stood at Rs 2,278.4 crore, up 5.49% YoY.

In its global generics business, North America contributed Rs 3,412.3 crore in revenue, a 11% year-on-year decline. Revenue from Europe surged 142% to Rs 1,274.4 crore, The India business generated revenue of Rs 1,471.1 crore, registering an 11% YoY.

Revenue from Pharmaceutical Services and Active Ingredients (PSAI) came in at Rs 818.1 crore, a 7% YoY increase.

Co-Chairman & MD, G V Prasad, said: 'We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio. The pricing pressure on Lenalidomide is expected to intensify in the U.S. generics market. We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development.'

Hyderabad-based Dr. Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

Top
Attention Investor:
Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers/Depository Participant.     KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, ,Mutual ).    No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.